An Open-Label Feasibility Study of Nintedanib Combined With Docetaxel in Japanese Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of First-Line Chemotherapy

Cancer Chemotherapy and Pharmacology - Germany

doi 10.1007/s00280-018-3649-x